Clinical trial
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's…
NCT00142155 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00142155 |
|---|---|
| Title | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia |
| Official title | Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Rituximab, monoclonal antibodies |
| Enrollment | 300 |
| Start date | Jan 1, 2002 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Jun 27, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: